Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX
Quoin Pharmaceuticals — Cellect Biotechnology — Investor Presentation (November 2017)
22 slides from Quoin Pharmaceuticals's investor presentation, Nov 2, 2017
Slide 1: Enabling Stem Cells - Corporate Presentation 2017
Enabling Stem Cells» Corpora sentation 2017 GSELE=CT
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation inlucos statements that ao, or may be doomed, fontarloking statements" In some case, these fowarlookigslterents canbe identifi by tho use of forwar-looking temindogy,cucing th terms “beleves,”"estmas”“anflepates“oxpects “plans "ites "may. coud, "might “sh
Slide 3: Investment Highlights
Investment Highlights NASDAQ:APOP Cellect represents potentially transformational technology Cellect technology aims to enable Stem Cells mass production for pharma, medical and research uses More effective, safer and less costly transplant procedures using Cellect platform technology is, expected t
Slide 4: Experienced Management Team / Advisors
Experienced Management Team / Advisors Dr. Shai Yarkoni MD, PhD, Co- Founder & CEO ‘Senior executive in the biotechnology industry Founder and CEO of Targt.n Lid, a cancer biotech therapeutics company. Founded and, unl recently, managed Bio-Negow. Eyal Leibovitz, CFO ‘ore than 25 years of experience
Slide 5: Regenerative Vs. Treatment medicine
Regenerative Vs. Treatment medicine The holy grail of medicine — stop fixing by chemicals, by poisons, radiation and massive surgery. Instead - replace the damaged tissues and organs using revolutionary Stem Cells technologies. C=LL=ECT
Slide 6: For Stem Cells to "work" there is a need for Purity and Quantity minima
For Stem Cells to “work” there is a need for Purity and Quantity minima. Hundreds of companies with stem cells products encounter poor availability and purity of raw material (stem cells). A safe, efficient and cost effective selection process for stem cells enabling mass production of raw material
Slide 7: The need
The need To enable mass market Stem Cells treatments there is an urgent, unmet need for ... Stem Cells as raw material. There is a clear need for enabling tools for rapid and cost effective manufacturing of quality Stem Cells. 7 C=LL=ECT
Slide 8: Cellect has the enabling platform for mass-production of quality stem cells
Slide 9: Scalable
Scalable From test tube to industrial-level drum size C=LL=ECT
Slide 10: Unattractive Trade-offs with Current Procedures
Unattractive Trade-offs with Current Procedures Bone Marrow Transplant Effective & highly toxic Non-toxic & ineffective Donor Sample > 50% GvHD Incidence if no selection 10 Lab Procedure Morphological Cell Selection Biomarker selection reduces number of stem cells delivered to patients HSCT Transpla
Slide 11: Our solution
Our solution * Cellect's procedure and containers create a closed hostile environment for rejection causing cells * Container walls are coated with a protein that triggers cell death or apoptosis in mature cells (ApoTainer®) + Incontrast, stem cells flourish in environments where normal cells die +
Slide 12: Efficacy Study- Improvement of a GvHD Clinical Score
Efficacy Study- Improvement of a GvHD Clinical Score A © contro! * A025 7 “= Asi00 . 6 gos a Bo: & . 1 ° days post tansplantation Clinical score of NSG transplanted mice, Each symbol represents the mean value for each group SEM. Untreated (n=10), AG25 (n=10 ) and AG100 (n=10). RFP otal, BUT Conon? C
Slide 13: Cellect in the Value Chain
Cellect in the Value Chain Stem Cell product high-level process Two hours Qo Cellect’s cost effective Ss selection makes expansion _@@ redundant 3 $ ° Ce Raw Material Selection Expansion Currently days to weeks Using current technology this stage Currently becomes a major takes days barrier and mand
Slide 14: Cellect Vs. Alternatives
Cellect Vs. Alternatives *Current Procedures *Cellect 2 hours Risk of GVHD Vs Rate of Infection Days or Weeks = Feanz of complex lab work Procedure Cost > 50% 0- 10% Parallel Chemotherapy Wide Minimal High Low Months Days ~ $70,000 *At least 50% less Total cost of procedure ~ $300,000 *At least 50%
Slide 15: Business strategy
Business strategy + Cellect provides enabling technology + Aiming for strategic licensing deals (upfront, milestones & royalties) with the Pharma, Biotech and Medtech players + Medical proof of concept through consumable medical devices + First mover advantage in a (Company estimated) multi-billion
Slide 16: Business Model
Business Model 4. IP Licensing — Upfront fee + milestone payments 2. Royalties ~ Tiered on net sales per each customers’ unit Product sold (TBD separately with each customer). + Comparable companies with similar business models: + Moderna + Abgenix + Medarex 16 C=LL=ECT
Slide 17: Clinical Program
Clinical Program ApoGraft Apotainer eenromimae > MSC eee Ey 2016 2017 2018 2019 2020 ” C=LL=ECT
Slide 18: ApoGraft Phase I/II Clinical Trial
ApoGraft Phase I/II Clinical Trial Location Israel (Rambam Medical Center in cooperation with Shaarei Tzedek Hospital) An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of- Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease Trial Trial group 12 match
Slide 19: Strong IP Protection
Strong IP Protection 7 families of global patent applications (4 already issued) + Patent for the concept of using apoptosis-inducing agents for stem cells selection + Patents for composition of matter of ApoTainers™ + Patents covering methods of use + Patents covering method of manufacturing ApoTai
Slide 20: Solid balance sheet with $~9.5 M of cash as of 9/30/2017; No loans
Solid balance sheet with $~9.5 M of cash as of 9/30/2017; No loans Sufficient cash to support Phase Il clinical trial and pipeline development Ordinary shares outstanding - ~120 million (~6 million ADRs) IPO on NASDAQ in 2016. De-listed from the TASE (Sep 2017) Holdings, Founders 36.91% NASDAQ, TASE
Slide 21: Summary
Summary NASDAQ:APOP 2 Cellect represents potentially transformational technology Collect technology aims to enable Stem Cells mass production for pharma, medical and research uses More effective, safer and less costly transplant procedures using Cellect expected to drive initial commercial demand al
Slide 22: em (ets
em (ets
Cellect Biotechnology — Investor Presentation (November 2017) on 6ix